Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Bioorg Med Chem
2009 Sep 01;1717:6463-80. doi: 10.1016/j.bmc.2009.05.085.
Show Gene links
Show Anatomy links
Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors.
Mosley CA
,
Myers SJ
,
Murray EE
,
Santangelo R
,
Tahirovic YA
,
Kurtkaya N
,
Mullasseril P
,
Yuan H
,
Lyuboslavsky P
,
Le P
,
Wilson LJ
,
Yepes M
,
Dingledine R
,
Traynelis SF
,
Liotta DC
.
???displayArticle.abstract???
The synthesis and structure-activity relationship analysis of a novel class of amide-based biaryl NR2B-selective NMDA receptor antagonists are presented. Some of the studied compounds are potent, selective, non-competitive, and voltage-independent antagonists of NR2B-containing NMDA receptors. Like the founding member of this class of antagonists (ifenprodil), several interesting compounds of the series bind to the amino terminal domain of the NR2B subunit to inhibit function. Analogue potency is modulated by linker length, flexibility, and hydrogen bonding opportunities. However, unlike previously described classes of NR2B-selective NMDA antagonists that exhibit off-target activity at a variety of monoamine receptors, the compounds described herein show much diminished effects against the hERG channel and alpha(1)-adrenergic receptors. Selections of the compounds discussed have acceptable half-lives in vivo and are predicted to permeate the blood-brain barrier. These data together suggest that masking charged atoms on the linker region of NR2B-selective antagonists can decrease undesirable side effects while still maintaining on-target potency.
Akazawa,
Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats.
1994, Pubmed
Akazawa,
Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats.
1994,
Pubmed
Barta-Szalai,
Oxamides as novel NR2B selective NMDA receptor antagonists.
2004,
Pubmed
Beal,
Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
1992,
Pubmed
Beal,
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
1992,
Pubmed
Borza,
Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.
2003,
Pubmed
Borza,
NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore.
2006,
Pubmed
Boyce,
Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn.
1999,
Pubmed
Chazot,
The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies.
2004,
Pubmed
Chenard,
(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses.
1995,
Pubmed
Chenard,
Antagonists selective for NMDA receptors containing the NR2B subunit.
1999,
Pubmed
Curtis,
Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists.
2003,
Pubmed
Dickenson,
Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation.
1987,
Pubmed
Dickenson,
The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord.
1997,
Pubmed
Dingledine,
The glutamate receptor ion channels.
1999,
Pubmed
Dirnagl,
Pathobiology of ischaemic stroke: an integrated view.
1999,
Pubmed
Dunah,
Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
2000,
Pubmed
Erreger,
Glutamate receptor gating.
2004,
Pubmed
Estrada Sánchez,
Excitotoxic neuronal death and the pathogenesis of Huntington's disease.
2008,
Pubmed
Fan,
N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.
2007,
Pubmed
Finlayson,
Acquired QT interval prolongation and HERG: implications for drug discovery and development.
2004,
Pubmed
Fischer,
Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro.
1997,
Pubmed
,
Xenbase
Gallagher,
Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor.
1996,
Pubmed
Gallagher,
Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions.
1998,
Pubmed
Gladstone,
Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions.
2002,
Pubmed
Gogas,
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
2006,
Pubmed
Hallett,
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
2004,
Pubmed
Henneberry,
The role of neuronal energy in the neurotoxicity of excitatory amino acids.
1989,
Pubmed
Ilyin,
Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
1996,
Pubmed
,
Xenbase
Jamieson,
Medicinal chemistry of hERG optimizations: Highlights and hang-ups.
2006,
Pubmed
Jarvis,
The novel N-methyl-D-aspartate (NMDA) antagonist CGS 19755 prevents ischemia-induced reductions of adenosine A1, NMDA, and PCP receptors in gerbil brain.
1988,
Pubmed
Kew,
A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.
1996,
Pubmed
Kew,
State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist.
1998,
Pubmed
,
Xenbase
Lehmann,
CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist.
1988,
Pubmed
Li,
Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease.
2003,
Pubmed
Lipton,
Molecular mechanisms of trauma-induced neuronal degeneration.
1993,
Pubmed
Lipton,
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
2004,
Pubmed
Loftis,
The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications.
2003,
Pubmed
Marinelli,
Homology modeling of NR2B modulatory domain of NMDA receptor and analysis of ifenprodil binding.
2007,
Pubmed
Mayer,
Structure and function of glutamate receptor ion channels.
2004,
Pubmed
McCauley,
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.
2004,
Pubmed
Miller,
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
2005,
Pubmed
Mony,
Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors.
2009,
Pubmed
,
Xenbase
Monyer,
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.
1994,
Pubmed
Nikam,
NR2B selective NMDA receptor antagonists.
2002,
Pubmed
Olney,
Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies.
1997,
Pubmed
Park,
The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat.
1988,
Pubmed
Perin-Dureau,
Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors.
2002,
Pubmed
,
Xenbase
Preskorn,
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
2008,
Pubmed
Robinson,
Memantine: a review of its use in Alzheimer's disease.
2006,
Pubmed
Sandkühler,
Induction of long-term potentiation at spinal synapses by noxious stimulation or nerve injury.
1998,
Pubmed
Snyder,
Regulation of NMDA receptor trafficking by amyloid-beta.
2005,
Pubmed
Standaert,
Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat.
1994,
Pubmed
Tahirovic,
Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
2008,
Pubmed
,
Xenbase
Traynelis,
Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit.
1998,
Pubmed
,
Xenbase
Wang,
NMDA/NR2B selective antagonists in the treatment of ischemic brain injury.
2005,
Pubmed
Waxman,
N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease.
2005,
Pubmed
Wei,
Genetic enhancement of inflammatory pain by forebrain NR2B overexpression.
2001,
Pubmed
Whetsell,
Current concepts of excitotoxicity.
1996,
Pubmed
Williams,
Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
1993,
Pubmed
,
Xenbase
Wong,
The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
1986,
Pubmed
Wong,
Expression and characterization of soluble amino-terminal domain of NR2B subunit of N-methyl-D-aspartate receptor.
2005,
Pubmed
Woodward,
In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites.
1995,
Pubmed
,
Xenbase
